Ovid Therapeutics Inc (OVID) - Total Assets
Based on the latest financial reports, Ovid Therapeutics Inc (OVID) holds total assets worth $63.85 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Ovid Therapeutics Inc net assets for net asset value and shareholders' equity analysis.
Ovid Therapeutics Inc - Total Assets Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Ovid Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Ovid Therapeutics Inc's total assets of $63.85 Million consist of 60.7% current assets and 39.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $92.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Ovid Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see OVID market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ovid Therapeutics Inc's current assets represent 60.7% of total assets in 2024, a decrease from 99.8% in 2014.
- Cash Position: Cash and equivalents constituted 28.5% of total assets in 2024, down from 99.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 0.1% of total assets.
Ovid Therapeutics Inc Competitors by Total Assets
Key competitors of Ovid Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Ovid Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.24 | 5.66 | 3.39 |
| Quick Ratio | 4.24 | 5.66 | 3.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $22.03 Million | $54.20 Million | $52.78 Million |
Ovid Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Ovid Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.27 |
| Latest Market Cap to Assets Ratio | 1.10 |
| Asset Growth Rate (YoY) | -36.0% |
| Total Assets | $92.17 Million |
| Market Capitalization | $101.12 Million USD |
Valuation Analysis
Above Book Valuation: The market values Ovid Therapeutics Inc's assets above their book value (1.10x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Ovid Therapeutics Inc's assets decreased by 36.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ovid Therapeutics Inc (2014–2024)
The table below shows the annual total assets of Ovid Therapeutics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $92.17 Million | -36.01% |
| 2023-12-31 | $144.03 Million | -7.24% |
| 2022-12-31 | $155.27 Million | -20.19% |
| 2021-12-31 | $194.54 Million | +156.23% |
| 2020-12-31 | $75.93 Million | -6.08% |
| 2019-12-31 | $80.84 Million | +69.66% |
| 2018-12-31 | $47.65 Million | -46.73% |
| 2017-12-31 | $89.46 Million | +68.70% |
| 2016-12-31 | $53.03 Million | -24.65% |
| 2015-12-31 | $70.38 Million | +1348.65% |
| 2014-12-31 | $4.86 Million | -- |
About Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and pediatric drug-resistant epilepsies; and OV350, a small molecule dire… Read more